Sign in

Private company

Oncternal Therapeutics, Inc.

In its 2024 annual report the company says: “Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. We have dosed and continue to enroll patients with mCRPC under Study ONCT-534-101 (NCT05917470).”4 It is headquartered in Memphis, United States.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersMemphis, United States2
  • Incorporated inDE3
  • Business address12230 El Camino Real, Suite 230, San Diego, Ca 921303
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300QZ85LIXQ8O7P722
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE PRENTICE-HALL CORPORATION SYSTEM, INC., 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 36928362

See how the biggest companies compare on our leaderboards

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on prostate cancer and hematological malignancies. We expect partnerships and collaborations to be essential for implementing our broader development strategy. The following table summarizes our current development programs:4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-5313.9%Operating margin5
-5029.2%Net margin5
-47.3%Revenue growth, 20235
-131.4%Return on equity5

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Other costs100¢$785.0K

Out of $785.0K in revenue.5 The company lost money this year.

Financial statements

Revenue67895$785.0K in 2023−69% since 2018
0$2.0M$4.0M$6.0M2018: $2.5M$2.5M20182019: $2.4M$2.4M2019−4%2020: $3.4M$3.4M2020+39%2021: $4.3M$4.3M2021+28%2022: $1.5M$1.5M2022−65%2023: $785.0K$785.0K2023−47%
Operating income1067895-$41.7M in 2023+36% since 2017
-$60.0M-$40.0M-$20.0M02017: -$30.7M-$30.7M20172018: -$7.6M-$7.6M2018−75%2019: -$33.1M-$33.1M2019+336%2020: -$17.5M-$17.5M2020−47%2021: -$31.4M-$31.4M2021+79%2022: -$44.9M-$44.9M2022+43%2023: -$41.7M-$41.7M2023−7%
Net income1067895-$39.5M in 2023+30% since 2017
-$60.0M-$40.0M-$20.0M02017: -$30.4M-$30.4M20172018: -$6.6M-$6.6M2018−78%2019: -$34.2M-$34.2M2019+420%2020: -$17.2M-$17.2M2020−50%2021: -$31.3M-$31.3M2021+82%2022: -$44.2M-$44.2M2022+41%2023: -$39.5M-$39.5M2023−11%
Fiscal year2017201820192020202120222023
Revenue$2.5M6$2.4M7$3.4M8$4.3M9$1.5M5$785.0K5
Research and development$06$07$08$09$09
Operating expenses$35.7M9$46.4M5$42.5M5
Operating income-$30.7M10-$7.6M6-$33.1M7-$17.5M8-$31.4M9-$44.9M5-$41.7M5
Interest$1.0K6
Income tax$09$05$05
Net income-$30.4M10-$6.6M6-$34.2M7-$17.2M8-$31.3M9-$44.2M5-$39.5M5
Earnings per share-$1.7514-$0.649-$16.805-$13.435
Earnings per share (diluted)-$1.7514-$0.649-$16.805-$13.435
Shares (weighted, basic)49.3M shares92.6M shares52.9M shares5
Shares (weighted, diluted)49.3M shares92.6M shares52.9M shares5

Compare Oncternal Therapeutics, Inc. with another company

Corporate structure

Oncternal Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Oncternal Therapeutics, Inc.

  • VANGUARD GROUP INC Filed SC 13G/A on Oncternal Therapeutics, Inc., latest Feb 13, 2024
  • BlackRock Filed SC 13G on Oncternal Therapeutics, Inc., latest Jul 8, 2022 (2 filings since Feb 4, 2022)
  • Oncternal Therapeutics, Inc. Memphis, Tennessee, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Oncternal Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Operating-lease assets (leased space)$258.0K5 Dec 31, 2023$87.0K5 Dec 31, 2022+196.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.7M5 Dec 31, 2023$37.1M5 Dec 31, 2022−82.0%
Marketable securities, current$27.6M5 Dec 31, 2023$26.6M5 Dec 31, 2022+3.7%
Debt securities available for sale$55.7M9 Dec 31, 2022

Leadership

Who has led Oncternal Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mitchell Shuster Steiner2006–2014
  2. Marc Steven Hanover2014–2018
  3. James B. Breitmeyer2019–2024

Chair

  1. Robert James Wills2015–2018

President

  1. Marc Steven Hanover2007–2014
  2. James B. Breitmeyer2019

Chief financial officer

  1. Mark Edward Mosteller2006–2013
  2. Richard G. Vincent2019–2024

Chief operating officer

  1. Marc Steven Hanover2007–2014
2010201520202025
Board members and other officers (42)

Former names

  • GTX INC /DE/Jan 30, 2004 to Jun 11, 20193
  • GTX INC/TNAug 21, 2003 to Jan 15, 20043

Timeline

  1. Nov 25, 20248-K Listing notice or transfer61
  2. Nov 14, 20248-K Exit or restructuring costs; Executive or director change62
  3. Sep 12, 20248-K Exit or restructuring costs; Executive or director change; Other events63
  4. Aug 8, 20248-K Results of operations64
  5. Jun 21, 20248-K Shareholder vote65
  6. May 9, 20248-K Results of operations66
  7. Mar 7, 20248-K Results of operations67
  8. Jan 23, 20248-K Entered a material agreement68
  9. Jan 5, 20248-K Results of operations; Change to shareholders' rights; Bylaws or fiscal year changed69
  10. Nov 9, 20238-K Results of operations70
  11. Oct 6, 20238-K Listing notice or transfer71
  12. Sep 14, 20238-K Shareholder vote72
  13. Jun 11, 2019New chief executive James B. Breitmeyer becomes CEO15
  14. Apr 7, 2014New chief executive Marc Steven Hanover becomes CEO16
  15. Mar 13, 2006New chief executive Mitchell Shuster Steiner becomes CEO17
  16. Sep 4, 2003Founded Oncternal Therapeutics, Inc. is founded2

Calendar

When it reported results

  1. Aug 8, 2024Reported quarterly or annual results64
  2. May 9, 2024Reported quarterly or annual results66
  3. Mar 7, 2024Reported quarterly or annual results67
  4. Jan 5, 2024Reported quarterly or annual results69
  5. Nov 9, 2023Reported quarterly or annual results70
  6. Aug 10, 2023Reported quarterly or annual results73
  7. May 4, 2023Reported quarterly or annual results74
  8. Apr 3, 2023Reported quarterly or annual results75

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

190 filings to the SEC since October 2021: 4 annual reports, 10 quarterly reports, 38 major events, 93 insider forms, 3 large holders, 42 other. The latest 20:

  1. Mar 31, 2025EFFECT EDGAR
  2. Mar 31, 2025EFFECT EDGAR
  3. Mar 31, 2025EFFECT EDGAR
  4. Mar 31, 2025EFFECT EDGAR
  5. Mar 31, 2025EFFECT EDGAR
  6. Mar 31, 2025EFFECT EDGAR
  7. Mar 27, 202515-12G EDGAR
  8. Mar 27, 2025S-8 POS EDGAR
  9. Mar 27, 2025S-8 POS EDGAR
  10. Mar 27, 2025S-8 POS EDGAR
  11. Mar 27, 2025S-8 POS EDGAR
  12. Mar 27, 2025S-8 POS EDGAR
  13. Mar 27, 2025S-8 POS EDGAR
  14. Mar 27, 2025S-8 POS EDGAR
  15. Mar 27, 2025S-8 POS EDGAR
  16. Mar 27, 2025S-8 POS EDGAR
  17. Mar 27, 2025S-8 POS EDGAR
  18. Mar 27, 2025S-8 POS EDGAR
  19. Mar 27, 2025S-8 POS EDGAR
  20. Mar 27, 2025POS AM EDGAR

The 190 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

23 open-market trades by officers, directors and large owners since October 2021: 22 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 8, 2024Wills Robert JamesDirectorBuy3,086$8.96$27.7KForm 4
Mar 28, 2024Wills Robert JamesDirectorBuy6,914$8.48$58.6KForm 4
Feb 23, 2024HALE DAVID FDirectorBuy980$9.04$8.9KForm 4
Feb 23, 2024Wills Robert JamesDirectorSale980$9.04$8.9KForm 4
Jun 14, 2023Kaufmann Gunnar F.Chief Scientific OfficerBuy3,000$0.36$1.1KForm 4
Jun 12, 2023Kaufmann Gunnar F.Chief Scientific OfficerBuy25,000$0.35$8.8KForm 4
Apr 14, 2023BREITMEYER JAMES BChief Executive OfficerBuy50,000$0.30$15.0KForm 4
Apr 14, 2023Yazji SalimChief Medical OfficerBuy5,000$0.30$1.5KForm 4
Apr 13, 2023BREITMEYER JAMES BChief Executive OfficerBuy100,000$0.29$29.0KForm 4
Apr 13, 2023Yazji SalimChief Medical OfficerBuy10,000$0.29$2.9KForm 4
Apr 13, 2023Leavitt Chase C.General Counsel/SecretaryBuy10,000$0.29$2.9KForm 4
Apr 13, 2023VINCENT RICHARD GChief Financial OfficerBuy30,000$0.30$9.0KForm 4
Apr 12, 2023Yazji SalimChief Medical OfficerBuy10,000$0.29$2.9KForm 4
Apr 12, 2023Leavitt Chase C.General Counsel/SecretaryBuy15,000$0.29$4.3KForm 4
Mar 28, 2022VINCENT RICHARD GChief Financial OfficerBuy2,500$1.40$3.5KForm 4
Mar 25, 2022VINCENT RICHARD GChief Financial OfficerBuy2,497$1.48$3.7KForm 4
Mar 24, 2022VINCENT RICHARD GChief Financial OfficerBuy3$1.45$4Form 4
Jan 28, 2022VINCENT RICHARD GChief Financial OfficerBuy2,500$1.65$4.1KForm 4
Jan 28, 2022Leavitt Chase C.General Counsel/SecretaryBuy5,000$1.63$8.2KForm 4
Jan 27, 2022VINCENT RICHARD GChief Financial OfficerBuy10,000$1.75$17.5KForm 4

All 23 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$301.0K 2020–2020
Money received by yearMoney received by year, 2020–2020: $301.0K in all. PPP loans $301.0K.$0$100K$200K$300K$400K2020 · PPP loans: $301.0K2020
Figures by year
YearPPP loansTotal
2020$301.0K$301.0K

PPP loans

Paycheck Protection Program loans of $150,000 and up, approved April 2020 to July 2021, from the SBA78. Matched to this company by name and state.

  1. Apr 29, 2020$301.0K PPP loan (first draw) from Silicon Valley Bridge Bank NA78To ONCTERNAL THERAPEUTICS, INC, San Diego CA; $302.8K forgiven Dec 10, 2020

SEC filer profile

How Oncternal Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROncternal Therapeutics, Inc.1
  • CIK0001260990
  • Employer ID (EIN)62-17158071
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address12230 El Camino Real, Suite 230, San Diego, CA 921301
  • Phone(858) 434-11131
  • Shares outstanding2,959,645 as of Nov 1, 202413
  • Public float$18.8M as of Jun 30, 20235
  • On EDGAR sinceAug 21, 20031
  • Filings1,606 in all: 4 (811), 8-K (295), 10-Q (63), 3 (51), 4/A (47), SC 13G/A (44), SC 13D/A (32), 10-K (21)1
    All 46 form types

    424B5 (21), DEF 14A (19), EFFECT (19), SC 13G (19), ARS (12), CORRESP (12), S-3 (12), S-8 (12), S-8 POS (12), UPLOAD (10), D (8), FWP (7), POS AM (7), 10-K/A (6), 424B3 (6), 425 (6), DEFA14A (6), PRE 14A (6), SC 13D (6), 5 (5), 8-K/A (5), S-1/A (4), 10-Q/A (3), 3/A (3), CT ORDER (3), 144 (1), 15-12G (1), 25 (1), 424B4 (1), 5/A (1), 8-A12G (1), D/A (1), PRER14A (1), REGDEX (1), S-1 (1), S-3MEF (1), S-4 (1), S-4/A (1)

  • Latest filingsAnnual report (10-K) Mar 7, 2024
    Quarterly report (10-Q) Nov 6, 2024
    Proxy statement (DEF 14A) Apr 26, 2024
    Latest 8-K (8-K) Nov 25, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78